Maze Therapeutics (MAZE) Cash from Operations (2024 - 2026)

Maze Therapeutics has reported Cash from Operations for 3 years, with the latest figure at 39113000.0 in Q1 2026.

• Quarterly Cash from Operations fell 32.51% year-over-year to 39113000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 121537000.0 (down 273.93% YoY) and the FY2025 annual result came in at 111940000.0, down 247.38% from the prior year.
• Cash from Operations fell to 39113000.0 in Q1 2026 per MAZE's latest filing, from 27730000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 145048000.0 in Q2 2024 and troughed at 39113000.0 in Q1 2026.
• A 3-year average of 8344333.33 and a median of 24642000.0 in 2025 frame the typical range for Cash from Operations.
• The widest YoY moves for Cash from Operations: up 6.19% in 2025, down 120.72% in 2025.
• Over 3 years, Cash from Operations stood at 22452000.0 in 2024, then dropped by 23.51% to 27730000.0 in 2025, then tumbled by 41.05% to 39113000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 39113000.0, 27730000.0, and 24642000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.